drugset
drugset / Trial / NCT00773929

Safety Study of TAK-593 Given Orally in Subjects With Nonhematologic Advanced Cancer

NCT00773929 ↗

Phase 1 Completed 60 enrolled Millennium Pharmaceuticals, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and toxicity profile of TAK-593 and determine the maximum tolerated dose of TAK-593.

Timeline

Start
2009-01
Primary completion
2010-01
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-593 Small molecule 2 mg Oral

Indications

cancer